Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2020 · 10-Q
Revenue$56.75K$56.75K— vs Q1 2019 Net Income-$1.18M-$1.18MN/M vs Q1 2019 EPS Diluted-$0.19-$0.19N/M vs Q1 2019 Operating Income-$1,230,782N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-2168.8%
Net margin-2078.3%
ended Mar 31, 2020 · filed May 14, 2020 · 44 d after period end